Skip to main content Accessibility help
×
×
Home

A response to Birch and Gafni – some reasons to be cheerful about NICE

  • MARTHE GOLD (a1) and STIRLING BRYAN (a2)

Copyright

Corresponding author

*Correspondence to: Marthe Gold MD, MPH, Department of Community Health and Social Medicine, City University of New York Medical School, 138th Street and Convent Avenue – Harris 406, New York, NY 10031, USA. Email: goldmr@med.cuny.edu

References

Hide All
Birch, S. and Gafni, A. (2002), ‘On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales’, Health Economics, 11: 185191.
Braveman, P. and Gruskin, S. (2003), ‘Defining equity in health’, Journal of Epidemiology and Community Health, 57: 254258.
Bryan, S., Williams, I. and McIver, S. (2007), ‘Seeing the NICE side of cost-effectiveness analyses: a qualitative investigation of the use of CEA in NICE technology appraisals’, Health Economics.
Cookson, R., McDaid, D. and Maynard, A. (2001), ‘Wrong SIGN, NICE mess: is national guidance distorting allocation of resources?’, British Medical Journal, 323: 743745.
Davies, E. and Littlejohns, P. (2002), ‘Views of Directors of Public Health about NICE appraisal guidance: results of a postal survey’, Journal of Public Health Medicine, 24(4): 319325.
Department of Health (2006), ‘Departmental Report’, CM 6814, Department of Health Departmental Report, Presented to Parliament by the Secretary of State for Health and the Chief Secretary to the Treasury, May 2006.
Devlin, N. and Parkin, D. (2004), ‘Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis’, Health Economics, 13(5): 437452.
Fleck, L. (2006), ‘The costs of caring: Who pays? Who profits? Who panders?’, Hastings Center Report, 36(3): 1317.
Gafni, A. and Birch, S. (2003), ‘Inclusion of drugs in provincial benefit programs: should “reasonable decisions” lead to uncontrolled growth in expenditures?’, Canadian Medical Association Journal, 168: 849851.
Garber, A.M. (2004), ‘Cost-effectiveness and evidence evaluation as criteria for coverage policy’, Health Affairs, Web exclusive, 19 May: 284296.
Gold, M.R., Siegel, J.S.Russell, L. and Weinstein, M. (1996), Cost-effectiveness in Health and Medicine, New York: Oxford University Press.
Holahan, J. and Cook, A. (2005), ‘Changes in economic conditions and health insurance coverage, 2000–2004’, Health Affairs, 24, S3, W5: 489508.
Patented Medicine Price Review Board (2006), ‘Non-patented prescription drug prices reporting: Canadian and foreign price trends’, accessed 25 August 2006 at http://www.pmprb-cepmb.gc.ca/english/view.asp?x=496.
Sculpher, M., Drummond, M. and O’Brien, B. (2001), ‘Effectiveness, efficiency and NICE’, British Medical Journal, 322: 943944.
Smith, C., Cowan, C.Sensenig, A. and Catlin, A. (2006), ‘Health spending growth slows in 2004’, Health Affairs, 25(1): 186196.
Williams, I. and Bryan, S. (under review), ‘Cost effectiveness analysis and formulary decision making: evidence based policy or muddling through?’ (under review)
Williams, I., Bryan, S. and McIver, S. (2007), ‘How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the NICE approach’, Journal of Health Services Research and Policy.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Health Economics, Policy and Law
  • ISSN: 1744-1331
  • EISSN: 1744-134X
  • URL: /core/journals/health-economics-policy-and-law
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed